University College London (UCL) Cancer Institute, London, UK.
HCA Healthcare, Macmillan Cancer Centre, London, UK.
Br J Haematol. 2020 Nov;191(4):558-561. doi: 10.1111/bjh.17166.
The UK has made a well-recognised contribution to the international effort to understand and treat acute lymphoblastic leukaemia (ALL) in adults. Work done in the UK by numerous personnel over many years has been instrumental in developing novel risk stratifications, evaluating treatment strategies for adult patients with de novo and relapsed disease and in making novel scientific contributions. The UK has championed and achieved very high levels of recruitment to clinical trials and, in particular, is known for success in large, investigator-initiated randomised controlled trials. This historical review charts the progress of clinical research in adult ALL from its inception to the present day.
英国为国际上理解和治疗成人急性淋巴细胞白血病（ALL）做出了公认的贡献。多年来，英国众多人员的工作在开发新的风险分层、评估初治和复发成人患者的治疗策略以及做出新的科学贡献方面发挥了重要作用。英国一直倡导并实现了临床试验的高招募率，特别是在大型、由研究者发起的随机对照试验方面取得了成功。本回顾性历史研究描绘了成人 ALL 临床研究从起源到现在的进展。
